CBS 2019
CBSMD教育中心
中 文

动脉粥样硬化性心血管疾病

Abstract

Recommended Article

Primary Prevention Trial Designs Using Coronary Imaging: A National Heart, Lung, and Blood Institute Workshop Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy The Year in Cardiovascular Medicine 2020: Coronary Prevention: Looking back on the Year in Cardiovascular Medicine for 2020 in the field of coronary prevention is Professor Ramon Estruch, Dr Luis Ruilope, and Professor Francesco Cosentino. Mark Nicholls meets them The sinus venosus contributes to coronary vasculature through VEGFC-stimulated angiogenesis High-Risk Coronary Plaque Regression After Intensive Lifestyle Intervention in Nonbstructive Coronary Disease: A Randomized Study Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular DiseaseA Prespecified Analysis From the FOURIER Trial Association Between Depressive Symptoms and Incident Cardiovascular Diseases

GuidelineJune 13, 2019

JOURNAL:JAMA Article Link

Primary Prevention of Sudden Cardiac Death

A D. Beaser; Adam S. Cifu, MD; Hemal M. Nayak. Keywords: rhythem dysorder; sudden cardiac death; primary prevention; LVEF; heart failure; ventricular fibrillation

ABSTRACT

Ventricular arrhythmias range from benign premature ventricular contractions to ventricular fibrillation and can be asymptomatic or have sudden cardiac death as the first manifestation. Sudden cardiac death is a major public health problem, accounting for 50% of all cardiovascular death.1 Although a plurality of sudden cardiac death occurs in the general population with no apparent cardiac risk factors, the risk is greatest in patients with LVEF of less than 30%, clinical heart failure, prior aborted cardiac arrest, or coronary artery disease.2